Anthera Pharmaceuticals Names Christopher P. Lowe Chief Financial Officer
Posted on: Thursday, 6 December 2007, 09:00 CST
SAN MATEO, Calif., Dec. 6 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs for chronic and acute diseases, announced today the appointment of Christopher P. Lowe to the position of Vice President of Administration and Chief Financial Officer. Mr. Lowe will be reporting directly to Paul F. Truex, Anthera's President and Chief Executive Officer. "We are very pleased to add such a talented and seasoned executive to our team," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals. "His strong operational and financial expertise, and his broad experience with the private and public markets, will provide a valuable foundation for our next phase of rapid growth."
Mr. Lowe comes to Anthera from Asthmatx Inc., where he served as Vice President, Finance and Administration and Chief Financial Officer. Previously, he was Corporate Controller and Chief Accounting Officer for Peninsula Pharmaceuticals, Inc. Mr. Lowe also serves on the board of Hansen Medical. Mr. Lowe holds a B.S. in business administration from California Polytechnic State University, San Luis Obispo, and an MBA from Saint Mary's University in Texas.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a privately-held pharmaceutical development company committed to world-class development and commercialization of promising clinical products to address the unmet medical needs of patients with life-threatening chronic and acute inflammatory diseases. In 2006ÃÂ Anthera acquired worldwide rights (except Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family -- a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienesÃÂ prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novelÃÂ upstream steps in the inflammation cascade and have the potential to address a variety of diseases including: acute chest syndromeÃÂ acute lung injuryÃÂ acute respiratory distress syndromeÃÂ atherosclerosisÃÂ acute coronary syndromeÃÂ chronic obstructive pulmonary disease and psoriasis. In order to efficiently commercialize this platformÃÂ Anthera has brought together a proven management team with extensive experience in licensingÃÂ clinical researchÃÂ developmentÃÂ and commercialization of anti-inflammatory products. For more information please visit http://www.anthera.com/.
CONTACT: Anne Bowdidge (650) 218-6900 PR@anthera.com
Anthera Pharmaceuticals, Inc.
CONTACT: Anne Bowdidge of Anthera Pharmaceuticals, Inc.,+1-650-218-6900, PR@anthera.com
Web site: http://www.anthera.com/
Source: PRNewswire
Related Articles
- Anthera Initiates Acute Coronary Syndrome Study
- Anthera Pharmaceuticals Acquires the Worldwide Rights to a BAFF Inhibitor for the Treatment of Lupus and Other Autoimmune Diseases
- Anthera Pharmaceuticals, Inc. Appoints Donald Santel to Board of Directors
- Anthera Pharmaceuticals, Inc. Announces Appointment of Dr. James Pennington As Executive Vice President & Chief Medical Officer
- Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs
- Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Cardiovascular Program
- Dr. David D. Waters Joins Anthera Pharmaceuticals As Cardiovascular Research Fellow
- Anthera Pharmaceuticals Secures $36M Venture Financing to Initiate Clinical Programs
- Immtech Appoints Carol Ann Olson, MD to Senior Vice President of Pharmaceutical Development and Chief Medical Officer
 |
 |
User Comments (0)
RSS Feeds